Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer revision label was updated from **Revision: v3.5.2** to **Revision: v3.5.3**.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded Revision: v3.5.2; removed Revision: v3.5.0.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page. The old revision reference is no longer shown.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision updated to v3.4.3. The previous revision v3.4.2 has been superseded.SummaryDifference0.1%

- Check52 days agoChange DetectedNo substantive content additions or deletions were detected; the study details, eligibility criteria, and outcome measures remain unchanged.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision indicator updated to v3.4.2 and the government funding status notice (including the prior Revision: v3.4.1) was removed; no study content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.